Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice

References

• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182-6; PMID:4938153; http://dx.doi.org/10.1056/NEJM197111182852108
   PubMed Web of Science ®Google Scholar
• Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011;91(3):1071-121; PMID: 21742796; http://dx.doi.org/10.1152/physrev.00038.2010
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6(4):273-86; PMID: 17396134; http://dx.doi.org/10.1038/nrd2115
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8(8):592-603; PMID:18650835; http://dx.doi.org/10.1038/nrc2442
   PubMed Web of Science ®Google Scholar
• Bergers G and S Song The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol 2005;7(4):452-64; PMID:16212810; http://dx.doi.org/10.1215/S1152851705000232
   PubMed Web of Science ®Google Scholar
• Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002;160(3):985-1000; PMID:11891196; http://dx.doi.org/10.1016/S0002-9440(10)64920-6
   PubMed Web of Science ®Google Scholar
• Ghilardi C, Chiorino G, Dossi R, Nagy Z, Giavazzi R, Bani M. Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. BMC Genomics 2008;9:201; PMID:18447899; http://dx.doi.org/10.1186/1471-2164-9-201
   PubMed Web of Science ®Google Scholar
• Hofmeister V, Schrama D, Becker JC. Anti-cancer therapies targeting the tumor stroma. Cancer Immunol Immunother 2008;57(1):1-17; PMID:17661033; http://dx.doi.org/10.1007/s00262-007-0365-5
   PubMed Web of Science ®Google Scholar
• Zhao X, Bose A, Komita H, Taylor JL, Chi N, Lowe DB, Okada H, Cao Y, Mukhopadhyay D, Cohen PA et al. Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. J Immunol 2012;188(4):1782-8; PMID:22246626; http://dx.doi.org/10.4049/jimmunol.1101644
   PubMed Web of Science ®Google Scholar
• Chi Sabins N, Taylor JL, Fabian KP, Appleman LJ, Maranchie JK, Stolz DB, Storkus WJ. DLK1: a novel target for immunotherapeutic remodeling of the tumor blood vasculature. Mol Ther 2013;21(10):1958-68; PMID:23896726; http://dx.doi.org/10.1038/mt.2013.133
   PubMed Web of Science ®Google Scholar
• Espina AG, Méndez-Vidal C, Moreno-Mateos MA, Sáez C, Romero-Franco A, Japón MA, Pintor-Toro JA. Induction of Dlk1 by PTTG1 inhibits adipocyte differentiation and correlates with malignant transformation. Mol Biol Cell 2009;20(14):3353-62; PMID: 19477929; http://dx.doi.org/10.1091/mbc.E08-09-0965
   PubMed Web of Science ®Google Scholar
• Begum A, Kim Y, Lin Q, Yun Z. DLK1, delta-like 1 homolog (Drosophila), regulates tumor cell differentiation in vivo. Cancer letters 2012;318(1):26-33; PMID: 22142700; http://dx.doi.org/10.1016/j.canlet.2011.11.032
   PubMed Web of Science ®Google Scholar
• Kim Y, Lin Q, Zelterman D, Yun Z. Hypoxia-regulated delta-like 1 homologue enhances cancer cell stemness and tumorigenicity. Cancer research 2009;69(24):9271-80; PMID:19934310; http://dx.doi.org/10.1158/0008-5472.CAN-09-1605
   PubMed Web of Science ®Google Scholar
• Xu X, Liu RF, Zhang X, Huang LY, Chen F, Fei QL, Han ZG. DLK1 as a potential target against cancer stem/progenitor cells of hepatocellular carcinoma. Mol Cancer Ther 2012;11(3):629-38; PMID:22238367; http://dx.doi.org/10.1158/1535-7163.MCT-11-0531
   PubMed Web of Science ®Google Scholar
• Smas CM, Sul HS. Pref-1, a protein containing EGF-like repeats, inhibits adipocyte differentiation. Cell 1993;73(4):725-734; PMID:8500166; http://dx.doi.org/10.1016/0092-8674(93)90252-L
   PubMed Web of Science ®Google Scholar
• Nueda ML, Baladrón V, García-Ramírez JJ, Sánchez-Solana B, Ruvira MD, Rivero S, Ballesteros MA, Monsalve EM, Díaz-Guerra MJ, Ruiz-Hidalgo MJ et al. The novel gene EGFL9/Dlk2, highly homologous to Dlk1, functions as a modulator of adipogenesis. J Mol Biol 2007;367(5):1270-80; PMID:17320102; http://dx.doi.org/10.1016/j.jmb.2006.10.020
   PubMed Web of Science ®Google Scholar
• Sanchez-Solana B, Nueda ML, Ruvira MD, Ruiz-Hidalgo MJ, Monsalve EM, Rivero S, García-Ramírez JJ, Díaz-Guerra MJ, Baladrón V, Laborda J. The EGF-like proteins DLK1 and DLK2 function as inhibitory non-canonical ligands of NOTCH1 receptor that modulate each other's activities. Biochim Biophys Acta 2011;1813(6);1153-64; PMID:21419176; http://dx.doi.org/10.1016/j.bbamcr.2011.03.004
   PubMed Web of Science ®Google Scholar
• Baladron V, Ruiz-Hidalgo MJ, Nueda ML, Díaz-Guerra MJ, García-Ramírez JJ, Bonvini E, Gubina E, Laborda J. dlk acts as a negative regulator of Notch1 activation through interactions with specific EGF-like repeats. Exp Cell Res 2005;303(2):343-59; PMID:15652348; http://dx.doi.org/10.1016/j.yexcr.2004.10.001
   PubMed Web of Science ®Google Scholar
• Traustadóttir GÁ, Jensen CH, Thomassen M, Beck HC, Mortensen SB, Laborda J, Baladrón V, Sheikh SP, Andersen DC. Evidence of non-canonical NOTCH signaling: Delta-like 1 homolog (DLK1) directly interacts with the NOTCH1 receptor in mammals. Cellular Signalling 2016;28(4):246-254; PMID:26791579; http://dx.doi.org/10.1016/j.cellsig.2016.01.003
   PubMed Web of Science ®Google Scholar
• Sainson RCA, Harris AL. Regulation of angiogenesis by homotypic and heterotypic notch signalling in endothelial cells and pericytes: from basic research to potential therapies. Angiogenesis 2008;11(1):41-51; http://dx.doi.org/10.1007/s10456-008-9098-0
   PubMed Web of Science ®Google Scholar
• He Y, Zhang J, Donahue C, Falo LD Jr. Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity 2006;24(5):643-56; PMID:16713981; http://dx.doi.org/10.1016/j.immuni.2006.03.014
   PubMed Web of Science ®Google Scholar
• Wentink MQ, Huijbers EJ, De Gruijl TD, Verheul HM, Olsson AK, Griffioen AW. Vaccination approach to anti-angiogenic treatment of cancer. Biochim Biophys Acta 2015;1855(2):155-171; PMID:25641676; http://dx.doi.org/10.1016/j.bbcan.2015.01.005
   PubMed Web of Science ®Google Scholar
• Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis — correlation in invasive breast carcinoma. N Engl J Med 1991;324(1):1-8; PMID:1701519; http://dx.doi.org/10.1056/NEJM199101033240101
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62; PMID:15637262; http://dx.doi.org/10.1126/science.1104819
   PubMed Web of Science ®Google Scholar
• Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 2005;25(13):5675-86; PMID:15964822; http://dx.doi.org/10.1128/MCB.25.13.5675-5686.2005
   PubMed Web of Science ®Google Scholar
• Dengler VL, Galbraith M. Espinosa Jí, Transcriptional regulation by hypoxia inducible factors. Crit Rev Biochem Mol Biol 2014;49(1):1-15; PMID: 24099156; http://dx.doi.org/10.3109/10409238.2013.838205
   PubMed Web of Science ®Google Scholar
• Bertout JA, Majmundar AJ, Gordan JD, Lam JC, Ditsworth D, Keith B, Brown EJ, Nathanson KL, Simon MC. HIF2α inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc Natl Acad Sci USA 2009;106(34):14391-6; PMID:19706526; http://dx.doi.org/10.1073/pnas.0907357106
   PubMed Web of Science ®Google Scholar
• Kumar V, Gabrilovich DI. Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. Immunology 2014;143(4):512-9; PMID:25196648; http://dx.doi.org/10.1111/imm.12380
   PubMed Web of Science ®Google Scholar
• Van der Burg SH, Arens R, Ossendorp F, Van Hall T, Melief CJ. Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer 2016;16(4):219-233; PMID: 26965076; http://dx.doi.org/10.1038/nrc.2016.16
   PubMed Web of Science ®Google Scholar
• Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH. Therapeutic cancer vaccines. J Clin Invest 2015;125(9):3401-12; PMID:26214521; http://dx.doi.org/10.1172/JCI80009
   PubMed Web of Science ®Google Scholar
• Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, Yoshioka Y, Baba T, Konishi I, Mandai M. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer 2015;112(9):1501-9; PMID:25867264; http://dx.doi.org/10.1038/bjc.2015.101
   PubMed Web of Science ®Google Scholar
• Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation. Cancer Cell 2004;6(6):553-563; PMID: 15607960; http://dx.doi.org/10.1016/j.ccr.2004.10.011
   PubMed Web of Science ®Google Scholar
• Rivero S, Díaz-Guerra MJ, Monsalve EM, Laborda J, García-Ramírez JJ. DLK2 is a transcriptional target of KLF4 in the early stages of adipogenesis. J Mol Biol 2012;417(1-2):36-50; PMID:22306741; http://dx.doi.org/10.1016/j.jmb.2012.01.035
   PubMed Web of Science ®Google Scholar
• Rivero S, Ruiz-García A, Díaz-Guerra MJ, Laborda J, García-Ramírez JJ. Characterization of a proximal Sp1 response element in the mouse Dlk2 gene promoter. BMC Mol Biol 2011;12:52; PMID:22185379; http://dx.doi.org/10.1186/1471-2199-12-52
   PubMed Web of Science ®Google Scholar
• Culver C, Melvin A, Mudie S, Rocha S. HIF-1alpha depletion results in SP1-mediated cell cycle disruption and alters the cellular response to chemotherapeutic drugs. Cell Cycle 2011;10(8):1249-60; PMID:21412054; http://dx.doi.org/10.4161/cc.10.8.15326
   PubMed Web of Science ®Google Scholar
• Jean JC, George E, Kaestner KH, Brown LA, Spira A, Joyce-Brady M. Transcription factor Klf4, induced in the lung by oxygen at birth, regulates perinatal fibroblast and myofibroblast differentiation. PLoS One 2013;8(1):e54806; PMID:23372771 ; http://dx.doi.org/10.1371/journal.pone.0054806
   PubMed Web of Science ®Google Scholar
• Hofmann JJ, Iruela-Arispe ML. Notch signaling in blood vessels: who is talking to whom about what? Circ Res 2007;100(11):1556-68; PMID: 17556669; http://dx.doi.org/10.1161/01.RES.0000266408.42939.e4
   PubMed Web of Science ®Google Scholar
• Hellstrom M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007;445(7129):776-80; PMID:17259973; http://dx.doi.org/10.1038/nature05571
   PubMed Web of Science ®Google Scholar
• Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD, Thurston G. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006;444(7122):1032-7; PMID:17183313; http://dx.doi.org/10.1038/nature05355
   PubMed Web of Science ®Google Scholar
• Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, Kowalski J, Watts RJ, Callahan C, Kasman I et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006;444(7122):1083-7; PMID:17183323; http://dx.doi.org/10.1038/nature05313
   PubMed Web of Science ®Google Scholar
• Rebay I, Fleming RJ, Fehon RG, Cherbas L, Cherbas P, Artavanis-Tsakonas S. Specific EGF repeats of Notch mediate interactions with Delta and Serrate: implications for Notch as a multifunctional receptor. Cell 1991;67(4):687-99; PMID:1657403; http://dx.doi.org/10.1016/0092-8674(91)90064-6
   PubMed Web of Science ®Google Scholar
• Cordle J, Redfieldz C, Stacey M, Van der Merwe PA, Willis AC, Champion BR, Hambleton S, Handford PA. Localization of the delta-like-1-binding site in human Notch-1 and its modulation by calcium affinity. J Biol Chem 2008;283(17):11785-93; PMID:18296446; http://dx.doi.org/10.1074/jbc.M708424200
   PubMed Web of Science ®Google Scholar
• Reis M, Czupalla CJ, Ziegler N, Devraj K, Zinke J, Seidel S, Heck R, Thom S, Macas J, Bockamp E et al. Endothelial Wnt/β-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression. J Exp Med 2012;209(9):1611-27; PMID:22908324; http://dx.doi.org/10.1084/jem.20111580
   PubMed Web of Science ®Google Scholar
• Griffioen AW. Anti-angiogenesis: making the tumor vulnerable to the immune system. Cancer Immunol Immunother 2008;57(10): 1553-8; PMID:18438662; http://dx.doi.org/10.1007/s00262-008-0524-3
   PubMed Web of Science ®Google Scholar
• Bose A, Lowe DB, Rao A, Storkus WJ. Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model. Melanoma Res 2012;22(3):236-43; PMID:22504156; http://dx.doi.org/10.1097/CMR.0b013e3283538293
   PubMed Web of Science ®Google Scholar
• Bose A, Taylor JL, Alber S, Watkins SC, Garcia JA, Rini BI, Ko JS, Cohen PA, Finke JH, Storkus WJ. Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer 2011;129(9):2158-70; PMID:21170961; http://dx.doi.org/10.1002/ijc.25863
   PubMed Web of Science ®Google Scholar
• Lowe DB, Bose A, Taylor JL, Tawbi H, Lin Y, Kirkwood JM, Storkus WJ. Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology 2014;3(1):e27589; PMID:24734217; http://dx.doi.org/10.4161/onci.27589
   PubMed Web of Science ®Google Scholar
• Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, Wood L, Elson P, Garcia J, Dreicer R et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(20):6674-82; PMID:18927310; http://dx.doi.org/10.1158/1078-0432.CCR-07-5212
   PubMed Web of Science ®Google Scholar
• Mrass P, Takano H, Ng LG, Daxini S, Lasaro MO, Iparraguirre A, Cavanagh LL, von Andrian UH, Ertl HC, Haydon PG et al. Random migration precedes stable target cell interactions of tumor-infiltrating T cells. J Exp Med 2006;203(12):2749-2761; PMID:17116735; http://dx.doi.org/10.1084/jem.20060710
   PubMed Web of Science ®Google Scholar
• Boissonnas A, Fetler L, Zeelenberg IS, Hugues S, Amigorena S. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J Exp Med 2007;204(2):345-356; PMID:17261634; http://dx.doi.org/10.1084/jem.20061890
   PubMed Web of Science ®Google Scholar
• Facciponte JG, Ugel S, De Sanctis F, Li C, Wang L, Nair G, Sehgal S, Raj A, Matthaiou E, Coukos G et al. Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature. J Clin Invest 2014;124(4):1497-511; PMID:24642465; http://dx.doi.org/10.1172/JCI67382
   PubMed Web of Science ®Google Scholar
• Seavey MM, Maciag PC, Al-Rawi N, Sewell D, Paterson Y. An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model. J Immunol 2009;182(9):5537-46; PMID:19380802; http://dx.doi.org/10.4049/jimmunol.0803742
   PubMed Web of Science ®Google Scholar
• Blattman JN, Wherry EJ, Ha SJ, Van der Most RG, Ahmed R. Impact of epitope escape on PD-1 expression and CD8 T-cell exhaustion during chronic infection. J Virol 2009;83(9):4386-94; PMID: 19211743; http://dx.doi.org/10.1128/JVI.02524-08
   PubMed Web of Science ®Google Scholar
• Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013;5(200):200ra116; PMID:23986400; http://dx.doi.org/10.1126/scitranslmed.3006504
   PubMed Web of Science ®Google Scholar
• Jayaraman P, Sada-Ovalle I, Beladi S, Anderson AC, Dardalhon V, Hotta C, Kuchroo VK, Behar SM. Tim3 binding to galectin-9 stimulates antimicrobial immunity. J Exp Med 2010;207(11):2343-54; PMID:20937702; http://dx.doi.org/10.1084/jem.20100687
   PubMed Web of Science ®Google Scholar